ACM
XENE icon

Accent Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Accent Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-400
Closed -$15.7K – 218
2024
Q3 		$15.7K Hold
400
– – 0.01% 144
2024
Q2 		$15.6K Hold
400
– – 0.01% 138
2024
Q1 		$17.2K Hold
400
– – 0.01% 106
2023
Q4 		$18.4K Buy
+400
New +$14.1K 0.01% 138

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Accent Capital Management's XENE Position: Q4 2024 in Review

Accent Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2024, closing a stake of 400 shares — an estimated $15.7K sold.

Accent Capital Management first reported a position in XENE in Q4 2023 and held it in 4 quarters. The position peaked at $18.4K in Q4 2023. 209 funds tracked by Wall St. Rank hold XENE as of Q4 2024.

  • Accent Capital Management reported no remaining Xenon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Accent Capital Management sold 400 Xenon Pharmaceuticals shares in Q4 2024, an estimated $15.7K.
  • Accent Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Accent Capital Management's Xenon Pharmaceuticals position peaked at $18.4K in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2024.

Based on Accent Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.